Yes, bacteria can absolutely be infected by viruses. The viruses that specifically target bacteria are called bacteriophages (or simply “phages”), and they are the most abundant biological entities on the planet. Current estimates put the global population at roughly 1031 particles, outnumbering bacteria in most environments by a factor of about ten to one. These tiny predators shape ecosystems, drive bacterial evolution, and are now being explored as a potential alternative to antibiotics.
How Phages Find and Infect Bacteria
Bacteriophages are structurally simple. Each one consists of a genetic payload (DNA or RNA) encased in a protein shell. Many phages look strikingly alien under an electron microscope, with distinct “heads,” “tails,” and “legs” that function like a biological syringe. The tail fibers are the key to infection: their tips recognize and latch onto specific molecules on the surface of a bacterium, such as outer membrane proteins, sugar chains on the cell wall, or even flagella. This lock-and-key specificity means most phages can only infect a narrow range of bacterial species, or even specific strains within a species.
The well-studied phage T4, which infects E. coli, illustrates this nicely. It uses two sets of tail fibers: long fibers that initially grab onto a protein on the bacterial surface, and short fibers that lock onto sugar-fat molecules in the cell wall for a firm, irreversible grip. Once attached, the phage punches through the membrane and injects its genetic material directly into the bacterium’s interior, leaving the empty protein shell outside like a discarded syringe.
Two Infection Strategies: Destroy or Hide
Once inside, a phage follows one of two general playbooks.
In the lytic cycle, the phage immediately hijacks the bacterium’s own protein-building machinery to manufacture copies of itself. The bacterium becomes a virus factory, churning out new phage particles until it literally bursts open, releasing dozens or hundreds of new phages to find fresh hosts. The bacterium is destroyed in the process.
The lysogenic cycle is far more subtle. Instead of immediately replicating, the phage stitches its DNA into the bacterium’s own chromosome (or persists as a separate loop of DNA inside the cell). In this dormant state, the viral DNA is called a prophage. It gets copied every time the bacterium divides, silently passed to every daughter cell. The bacterium can live and reproduce normally for generations, carrying the hidden viral genome. But when conditions deteriorate, such as when nutrients run low or the cell is stressed, the prophage activates, switches to the lytic cycle, and destroys its host. Phages capable of this dormant strategy are called temperate phages.
Bacteria Fight Back
Bacteria haven’t been passive victims over billions of years of phage attack. They’ve evolved sophisticated defense systems, and one of them turned out to be one of the most important biotechnology tools ever discovered: CRISPR.
The CRISPR system works like a molecular immune memory. When a bacterium survives a phage infection, it can clip a small piece of the invading viral DNA and store it in a special region of its own genome. These stored snippets act as a reference library. If the same phage (or a close relative) attacks again, the bacterium produces small RNA molecules that match the stored snippet. These RNA guides pair with specialized proteins that scan incoming DNA for a match. When they find one, the proteins cut the invading DNA apart, neutralizing the threat. This is a true adaptive immune system, passed from parent to offspring through cell division.
Bacteria also use simpler defenses. Restriction enzymes act like molecular scissors that chop up any foreign DNA that enters the cell, provided it lacks a specific chemical tag the bacterium uses to mark its own DNA as “self.” Some bacteria go further, modifying the surface receptors that phages target so the virus can no longer attach in the first place.
How Phages Reshape Bacterial Evolution
Phage infection isn’t just destruction. It’s one of the major engines of bacterial evolution. When phages replicate inside a bacterium, they occasionally make mistakes during packaging, accidentally grabbing a chunk of the host bacterium’s DNA instead of their own. When that defective phage injects its payload into a new bacterium, it delivers bacterial genes from its previous host. This process, called transduction, moves genetic material between bacteria that might never otherwise exchange DNA.
There are two flavors. In generalized transduction, random segments of the host’s chromosome get swept up. In specialized transduction, genes located near the prophage insertion site get spliced into the viral genome, creating a hybrid molecule of phage and bacterial DNA. Either way, the receiving bacterium can incorporate useful new genes, potentially gaining traits like the ability to metabolize a new nutrient or resist an antibiotic. Over evolutionary time, this virus-mediated gene shuffling has been a major force in bacterial diversification.
Temperate phages contribute even when they’re dormant. A bacterium carrying a prophage can gain entirely new capabilities from the viral genes sitting in its chromosome, a phenomenon called lysogenic conversion. Some of the most dangerous bacterial toxins, including those responsible for cholera and diphtheria, are actually encoded by prophage DNA rather than the bacterium’s original genome.
Phages in Your Gut
Your digestive tract is home to a dense community of bacteriophages known as the gut phageome. This community plays a central role in shaping which bacteria thrive in your intestines and which get kept in check. In infants, the phageome is chaotic, with high rates of turnover as new bacteria and phages constantly shuffle through the developing gut. Over time, it stabilizes into a pattern unique to each person: a core set of phage types that persist for years, surrounded by a more variable cast that shifts with diet, antibiotic use, and other environmental factors.
In a healthy gut, phages appear to operate under a “piggyback the winner” dynamic. Rather than constantly killing the most successful bacteria, temperate phages tend to remain dormant inside thriving hosts, benefiting from their growth. Lysogenic bacteria even gain a competitive edge: about 1% of cells in a lysogenic population spontaneously release phage particles at any given time, and those particles can kill closely related bacteria that lack the prophage, effectively eliminating competitors.
When this balance breaks down, the consequences can be significant. In patients with inflammatory bowel diseases like Crohn’s disease and ulcerative colitis, researchers have observed a bloom of temperate phage particles alongside a drop in their host bacteria, suggesting that widespread prophage activation may be a hallmark of gut inflammation.
Phages and the Global Carbon Cycle
In the ocean, phages cause massive bacterial die-offs that fundamentally alter how carbon and nutrients cycle through marine ecosystems. When a phage bursts a bacterial cell, the contents spill into the surrounding water as dissolved organic matter. This process, called the viral shunt, redirects carbon that would have been consumed by larger organisms (like protists grazing on bacteria) and instead keeps it circulating among microbes. The surviving bacteria feed on the released material, and as they metabolize it, they regenerate inorganic nutrients like nitrogen and phosphorus that fuel algal growth.
Coastal seawater typically contains around 10 million phage particles per milliliter, and the global oceanic population is estimated at over 1030. At that scale, the viral shunt is a significant component of the global carbon cycle, influencing how much carbon stays dissolved in surface waters versus sinking to the deep ocean.
Phage Therapy for Drug-Resistant Infections
The precision with which phages target specific bacteria has sparked interest in using them as living antibiotics, particularly against drug-resistant infections. The concept, called phage therapy, actually predates antibiotics by decades but was largely abandoned in the West after penicillin became widely available. Now, with antibiotic resistance becoming a global crisis, phage therapy is getting a second look.
Early-phase clinical trials have shown that phage therapy is safe in humans. In one ongoing trial, a phage product targeting multidrug-resistant E. coli urinary tract infections reduced bacterial levels within four hours of administration, with complete symptom resolution by day ten in evaluated patients. But efficacy in larger, controlled trials has been harder to demonstrate. Many of the most compelling success stories come from individual case reports where patients also received conventional antibiotics, making it difficult to isolate the phage’s contribution.
No phage therapy product has received FDA approval for human use in the United States. Phage products are classified as biological drugs and must go through the same rigorous clinical trial process as any other therapeutic. Several candidates are currently in Phase 2 and Phase 3 trials, but the path to widespread approval remains long. The specificity that makes phages appealing also makes them tricky to develop: unlike a broad-spectrum antibiotic, a single phage product may only work against certain strains, requiring diagnostic testing to match the right phage to the right infection.